消化系统来源SMARCA4缺失性肿瘤的临床病理分析
该回顾性研究分析了18例消化系统来源SMARCA4缺失性肿瘤的临床病理特征、治疗及预后,并结合cBioPortal公共数据库实体瘤数据进行SMARCA4基因改变的生存分析。结果显示这类肿瘤分化差、侵袭性高、预后不佳,有限样本中生存数据呈两极化趋势,免疫联合化疗在部分晚期患者中显示较好疗效。
要点
- 消化系统SMARCA4缺失性肿瘤分化差,可表现为未分化癌,侵袭性高、预后不佳。
- 18例中16例Ki-67指数>50%,INI1(14/14)及Syn(12/15)阳性表达率较高。
- 数据库分析显示SMARCA4突变实体瘤患者总生存劣于未突变患者。
核心结论
- 消化系统来源SMARCA4缺失性肿瘤分化较差,可表现为未分化癌,部分有腺癌或神经内分泌分化倾向,侵袭性高、预后不佳。
- 有限样本量显示生存数据有两极化趋势。
研究设计与样本
- 回顾性收集2021年1月1日至2024年12月31日天津医科大学肿瘤医院病理诊断为消化系统来源SMARCA4缺失性肿瘤患者18例,分析临床病理特征及治疗预后
- 采用免疫组化染色检测BRG1。
- 利用cBioPortal中MSK-CHORD队列(24 950例患者的25 040例样本)和MSK-IMPACT队列(48 179例患者的54 331例样本)的实体瘤数据,围绕SMARCA4基因改变进行生存分析和基因突变谱分析。
主要发现
- 18例包括10例胃癌、4例胆囊/胆管癌、2例肝癌、2例结直肠癌;平均年龄62.8岁,男性14例、女性4例。
- 7例初诊晚期,其中5例存在≥2个远处器官转移;8例为未分化癌,2例低分化癌,5例倾向低分化腺癌,1例倾向神经内分泌癌,2例为未分化肉瘤。
- 18例中16例Ki-67指数>50%,INI1(14/14)及Syn(12/15)阳性表达率较高。
- 5例总生存不足6个月(其中3例为Ⅱ/Ⅲ期);6例总生存超过1年,其中4例接受根治性手术(2例胃癌接受免疫联合化疗围手术期治疗),2例初诊晚期接受免疫联合化疗总生存超过17个月且仍在免疫维持治疗中。
- 数据库分析显示实体瘤SMARCA4基因突变频率为5%,未携带SMARCA4突变患者总生存优于突变患者(MSK-CHORD队列:50.43和33.24个月,HR=0.743,P<0.001;MSK-IMPACT队列:44.05和35.60个月,HR=0.816,P<0.001)。
临床怎么用
- 对消化系统低分化或未分化肿瘤应检测BRG1以识别SMARCA4缺失性亚型。
- 该类肿瘤侵袭性高、预后不佳,需重视早期识别与密切随访。
- 部分初诊晚期患者接受免疫联合化疗可获得超过17个月总生存并维持治疗,提示免疫联合化疗可能为治疗选择。
局限性
- 本研究为单中心回顾性分析,样本量仅18例。
- 作者指出有限样本量显示生存数据有两极化趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinicopathological characteristics, treatment, and prognosis of SMARCA4-deficient tumors of digestive system origin, and to deepen the understanding of this tumor subtype. Methods: A retrospective analysis was conducted on 18 patients diagnosed with SMARCA4-deficient tumors of digestive system origin at Tianjin Medical University Cancer Institute and Hospital from January 1, 2021 to December 31, 2024. Their clinicopathological features, treatments, and prognoses were summarized. Immunohistochemical staining was used to detect BRG1. Using solid tumor data from the MSK-CHORD cohort (25 040 samples from 24 950 patients) and the MSK-IMPACT cohort (54 331 samples from 48 179 patients) in the public database cBioPortal, survival analysis and gene mutation profiling were performed focusing on SMARCA4 gene alterations. Results: The 18 SMARCA4-deficient tumors included 10 gastric cancers, 4 gallbladder/bile duct cancers, 2 liver cancers, and 2 colorectal cancers. The mean age of the patients was 62.8 years; there were 14 males and 4 females. Seven patients were initially diagnosed with advanced-stage disease, of whom 5 had metastases to ≥2 distant organs. Based on cytomorphology and immunohistochemistry (IHC) results, 8 cases were classified as undifferentiated carcinoma, 2 as poorly differentiated carcinoma, 5 as poorly differentiated adenocarcinoma, 1 as neuroendocrine carcinoma and 2 as undifferentiated sarcomas. Among the 18 patients, 16 had a Ki-67 index>50%, and high expression levels were observed for INI1 (14/14) and Syn (12/15). Regarding survival, 5 patients had an overall survival (OS) of <6 months, including 3 with stage Ⅱ/Ⅲ disease. Six patients had an OS exceeding 1 year; among them, 4 underwent radical surgery (2 patients with gastric cancer received perioperative immunotherapy combined with chemotherapy), and 2 patients initially diagnosed with advanced-stage disease received immunotherapy combined with chemotherapy, achieving an OS exceeding 17 months and are currently still on maintenance therapy. Database analysis results showed that the frequency of SMARCA4 gene mutations in solid tumors was 5%. Patients without SMARCA4 mutations had better OS than those with SMARCA4 mutations (MSK-CHORD cohort: 50.43 vs 33.24 months, HR=0.743, P<0.001; MSK-IMPACT cohort: 44.05 vs 35.60 months, HR=0.816, P<0.001). Conclusions: SMARCA4-deficient tumors of digestive system origin are poorly differentiated, may present as undifferentiated carcinoma, and some cases show differentiation tendencies toward adenocarcinoma or neuroendocrine carcinoma. These tumors are highly aggressive with poor prognosis. The limited sample size shows a polarized trend in survival data. 目的: 分析消化系统来源SMARCA4缺失性肿瘤的临床病理特征及治疗、预后情况,加深对这一亚型肿瘤的认识。 方法: 回顾性收集2021年1月1日至2024年12月31日就诊于天津医科大学肿瘤医院病理诊断为消化系统来源的SMARCA4缺失性肿瘤患者18例,分析总结其临床病理特征及治疗预后情况。采用免疫组化染色方法检测BRG1。利用公开数据库cBioPortal中MSK-CHORD队列(24 950例患者的25 040例样本)和MSK-IMPACT队列(48 179例患者的54 331例样本)的实体瘤数据,围绕SMARCA4基因改变进行生存分析和基因突变谱分析。 结果: 18例SMARCA4缺失性肿瘤包括10例胃癌,4例胆囊/胆管癌,2例肝癌,2例结直肠癌。患者平均年龄为62.8岁,男性14例,女性4例。7例患者为初诊晚期,其中5例存在≥2个远处器官转移。结合细胞形态及免疫组化结果,8例为未分化癌,2例为低分化癌,5例倾向为低分化腺癌,1例倾向神经内分泌癌,另有2例为未分化肉瘤。18例患者中,16例Ki-67指数>50%,INI1(14/14)及Syn(12/15)阳性表达率较高。从生存情况来看,5例患者总生存时间不足6个月,其中3例为Ⅱ/Ⅲ期。6例患者总生存时间超过1年,其中4例接受了根治性手术(2例胃癌患者接受免疫联合化疗围手术期治疗),2例患者为初诊晚期,接受免疫联合化疗,总生存时间超过17个月,目前仍在免疫维持治疗中。数据库分析结果显示,实体瘤患者SMARCA4基因突变频率为5%,未携带SMARCA4基因突变患者的总生存时间优于SMARCA4突变患者(MSK-CHORD队列:50.43和33.24个月,HR=0.743,P<0.001;MSK-IMPACT队列:44.05和35.60个月,HR=0.816,P<0.001)。 结论: 消化系统来源SMARCA4缺失性肿瘤分化较差,可表现为未分化癌,部分表现为腺癌、神经内分泌等分化倾向,侵袭性高,预后不佳,有限样本量显示生存数据有两极化趋势。.
引用
- Wang FX, Ning T, Bai M, et al. [Clinicopathological analysis of SMARCA4-deficient tumors of digestive system origin]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42331552. doi:10.3760/cma.j.cn112152-20251229-00643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。